Restorgenex - new directors

Restorgenex / Histogen
Looks like they are going ahead with the reverse merger as planned:

http://www.sec.gov/Archives/edgar/da..._8k-110113.htm

Quote from SEC filing:

'Effective November 1, 2013, Sol J. Barer, Ph.D. and Isaac Blech were elected by the Company’s board of directors (the “Board”) as new directors. Dr. Barer was also named Chairman of the Board and Mr. Blech was named Vice Chairman of the Board. Dr. Barer and Mr. Blech have also been appointed to serve on the Company’s Audit and Compensation Committees. Their compensation as board members has not yet been determined. Also effective November 1, 2013, Jerold Rubinstein resigned as Chairman of the Board but remains as Chairman of the Board’s Audit Committee and Chief Executive Officer.'

and what does it mean that all:confused::confused:
it tells us no more about the testing phases:(

histogen restrogenex fusion and is it effective?

Well I can say for certain now, Histogen say they have ceased pursuit of the merger agreement with Restorgenex.
Instead, they are now moving forward with Series B financing.